Intercept Pharmaceuticals, Inc. provided full-year 2023 Ocaliva net sales guidance to $320 million to $340 million.
Intercept Pharmaceuticals, Inc.
Equities
ICPT
US45845P1084
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+7.64% | 113B | |
+10.98% | 106B | |
+0.41% | 22.27B | |
-11.89% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-6.04% | 17.24B | |
+6.76% | 14.29B | |
+36.17% | 12.52B |